Skip to main content

New Products

  • Lupin launches generic HIV drug

    BALTIMORE — Lupin has launched a generic drug for treating HIV, following its victory in a patent-infringement suit in federal court, the Indian drug maker said Wednesday.

    Lupin's U.S. subsidiary launched its generic version of ViiV Healthcare's Trizivir (abacavir sulfate; lamivudine; zidovudine) tablets in the 300-mg/150-mg/300-mg strength. The launch follows a ruling by the U.S. District Court for the District of Delaware that the drug did not infringe on Viiv's patent.

  • Sibu launches Omega 7 product

    SALT LAKE CITY — Sibu Beauty, a skin care and supplement line made from the sea buckthorn berry, announced the Sibu Seven Omega 7 Pure Line. The product boasts the most potent, natural form of omega-7 (palmitoleic acid), the company said.

  • Amneal launches new GERD treatment

    BRIDGEWATER, N.J. — Amneal Pharmaceuticals has launched a new treatment for gastroesophageal reflux disease under a partnership with a South Korean drug maker.

    Amneal announced Tuesday the launch of esomeprazole strontium delayed-release capsules in the 49.3-mg strength, which it is marketing in the United States under a contract with Hanmi Pharmaceutical Co. The drug is expected to begin shipping Wednesday in 30-count bottles.

  • Greenstone launches authorized generic voriconazole for oral suspension

    PEAPACK, N.J. — Greenstone has launched a version of a drug used to treat fungal infections, the company said.

    Greenstone, the generics subsidiary of Pfizer, announced the introduction of voriconazole for oral suspension, an authorized generic version of Pfizer's Vfend. Authorized generics are branded drugs sold at a discount under their generic names.

    Greenstone is selling the drug in the 40 mg-per-milliliter strength. Vfend had sales of about $17.1 million during the 12-month period that ended in June, according to IMS Health.

     

  • Mylan, Banner settle cancer drug lawsuit with Eisai, Valeant

    PITTSBURGH — Mylan and a partnering company will be able to sell a generic version of a cancer drug starting in summer 2015, under a court settlement announced Tuesday.

    Mylan said that it and Banner Pharmacaps had reached a settlement agreement with Eisai and a subsidiary of Valeant Pharmaceuticals International to resolve a lawsuit filed over their generic version of Targretin (bexarotene) capsules in the 75-mg strength. The drug is used to treat certain forms of T-cell lymphoma.

  • Mistic introduces gift sets for the holidays

    CHARLOTTE, N.C. — Mistic, a maker of electronic cigarettes, on Monday announced that Walmart has added Mistic's Ultimate Gift Set to store shelves across the nation.  

  • Endo acquires NuPathe for $105 million

    MALVERN, Pa. – Endo Health Solutions will acquire the maker of a patch used to treat migraines that received Food and Drug Administration approval at the beginning of this year.

    Endo said Monday that it would buy NuPathe for $105 million. In January, the FDA approved NuPathe's patch, Zecuity, a disposable, single-use, battery-powered transdermal patch that delivers the drug sumatriptan, the most widely prescribed migraine medication.

X
This ad will auto-close in 10 seconds